三阴性乳腺癌(triple-negative breast cancer,TNBC)的主要治疗方式是化疗,而化疗耐药是TNBC治疗的难点.发现在TNBC细胞系(MDA-MB-231、BT-549)中,Nek2A的表达异常增高,Nek2A-siRNA转染TNBC细胞系,降低Nek2A表达后,TNBC细胞增殖降低,化疗药物联合Nek2A-siRNA组细胞增殖降低更明显.降低Nek2A表达可以增强紫杉醇及顺铂的化疗敏感性.检测裸鼠体内成瘤情况发现:Nek2A-siRNA联合紫杉醇(TAX)及顺铂(DDP)化疗药物组肿物最小.结果表明,Nek2A在TNBC中表达异常增高,并且降低Nek2A表达可以增强紫杉醇及顺铂化疗敏感性.
Expression of Nek2A in Triple Negative Breast Cancer and Its Relationship with Chemosensitivity
The main treatment of triple negative breast cancer(TNBC)is chemotherapy,and chemotherapy resistance is the difficulty of TNBC treatment.This study found that the expression of Nek2A was abnormally increased in TNBC cell lines(MDA-MB-231,BT-549).When Nek2A siRNA was transfected into TNBC cell lines and the expression of Nek2A was reduced,the proliferation of TNBC cells decreased.The combination of chemotherapy drugs and Nek2A siRNA resulted in a more significant decrease in cell proliferation.And it was found that reducing Nek2A expression can enhance the chemotherapy sensitivity of paclitaxel and cisplatin.Detection of tumor formation in nude mice revealed that the Nek2A siRNA combined with paclitaxel(TAX)and cisplatin(DDP)chemotherapy group had the smallest tumor mass.The results of this experiment indicate that the expression of Nek2A is abnormally increased in TNBC,and reducing Nek2A expression can enhance the sensitivity of paclitaxel and cisplatin chemotherapy.
breast cancertriple negative breast cancerchemosensitivityNek2A
NETL
NSTL
万方数据
